Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis Karl-Christian Bergmann, MD, Pascal Demoly,

Slides:

Advertisements

Similar presentations

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery Albertien A.C. Aukema,

Advertisements

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy Satya D. Narisety,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study Eli O. Meltzer, MD, Paul.

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD

Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy Ana I. Tabar, MD, PhD, Esozia Arroabarren, MD, Susana.

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis Alain Didier, MD,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood Zaraquiza Zolkipli, MSc,

Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy Julie Wang, MD, Stacie M. Jones,

Oral steroids and doxycycline: Two different approaches to treat nasal polyps Thibaut Van Zele, MD, PhD, Philippe Gevaert, MD, PhD, Gabriele Holtappels,

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Is 9 more than 2 also in allergic airway inflammation?

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy Robert A.

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study Peter Kenney, BSc, Ole Hilberg,

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms Natasha C. Gunawardana,

Joe K. Gerald, MD, PhD, Roni Grad, MD, William C. Bailey, MD, Lynn B

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy.

Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber Friedrich Horak, MD, Petra.

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Treatment of chronic autoimmune urticaria with omalizumab

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy Satya D. Narisety,

Reply Journal of Allergy and Clinical Immunology

Respiratory sensitization of a worker to the warehouse beetle Trogoderma variabile: An index case report Jonathan A. Bernstein, MD, Marjorie S. Morgan,

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis Natalija Novak, MD,

Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma Oliver.

Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial Hendrik.

Allergen-specific immunotherapy with recombinant grass pollen allergens Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

Daphne Koinis-Mitchell, PhD, Timothy Craig, DO, Cynthia A

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis Stephen R. Durham,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Cockroach allergens: Coping with challenging complexity

Autophagy: Nobel Prize 2016 and allergy and asthma research

House dust mite sublingual immunotherapy: Results of a US trial

Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? Marianne Witten, MD, PhD, Hans-Jørgen Malling, MD, Lars.

Local allergic rhinitis: Allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen Carmen Rondón, MD, PhD, Natalia.

Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study Alessandro.

Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy Julie Wang, MD, Stacie M. Jones,

Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years Ronald Dahl, MD,

Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet Stephen.

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma Bob Lanier, MD, Tracy Bridges,

Reply Journal of Allergy and Clinical Immunology

Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen–induced rhinoconjunctivitis

Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber

Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite–induced allergic.

Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity James N. Francis, PhD, Louisa.

Macrolide antibiotics and asthma treatment

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

Placental transfer of allergen-specific IgG but not IgE from a specific immunotherapy– treated mother Sabine Flicker, PhD, Katharina Marth, MD, Heinz.

Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization.

Dendritic cells in nasal mucosa of subjects with different allergic sensitizations Susanne M. Reinartz, MD, Joost van Tongeren, MD, Danielle van Egmond,

Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen Piyush Patel, MD, Tom Holdich, MBBS,

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

Safety and efficacy of repeated monthly carboplatin desensitization

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Presentation transcript:

Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis Karl-Christian Bergmann, MD, Pascal Demoly, MD, PhD, Margitta Worm, MD, Wytske J. Fokkens, MD, PhD, Teresa Carrillo, MD, PhD, Ana I. Tabar, MD, PhD, Hélène Nguyen, PharmD, Armelle Montagut, Robert K. Zeldin, MD Journal of Allergy and Clinical Immunology Volume 133, Issue 6, Pages 1608-1614.e6 (June 2014) DOI: 10.1016/j.jaci.2013.11.012 Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Study design. Participants recorded the occurrence and severity of their symptoms and use of rescue medications during screening (7 days) and once randomized at months 2, 4, 6, 15, and 18 (14 days) and during the primary periods (months 8-12 and months 20-24). Primary periods were defined from October 1 to December 31 of each study year. Journal of Allergy and Clinical Immunology 2014 133, 1608-1614.e6DOI: (10.1016/j.jaci.2013.11.012) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Symptom and rescue medication scores (FASYear1); ARTSS (A), ARMS (B), and ARSS (C). Observations for all variables were available for 136 participants in the 500IR group, 141 participants in the 300IR group, and 153 participants in the placebo group, except for ocular itching (131, 139, and 148 participants, respectively). *P < .05 (analysis of covariance, each of the 2 active groups vs the placebo group). Journal of Allergy and Clinical Immunology 2014 133, 1608-1614.e6DOI: (10.1016/j.jaci.2013.11.012) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 AAdSS (FASYear1 and FASYear2). Fourteen-day diaries were collected after each time point visit (months 2-10 and months 15-20) or preceding the month 12 and month 24 visits. Mean baseline ARTSSs (no rescue medication allowed) were 7.26 (500IR group), 6.94 (300IR group), and 6.79 (placebo group). *P < .05 (repeated-measures analysis of covariance mixed model, each of the 2 active groups vs the placebo group). Journal of Allergy and Clinical Immunology 2014 133, 1608-1614.e6DOI: (10.1016/j.jaci.2013.11.012) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Symptom and rescue medication scores (FASYear2); AAdSS (A), ARTSS (B), ARMS (C) and ARSS (D). Observations for all variables were available for 120 participants in the 500IR group, 132 participants in the 300IR group, and 137 participants in the placebo group, except for ocular itching (117, 131, and 134 participants, respectively). *P < .05 (analysis of covariance, each of the 2 active groups vs the placebo group). Journal of Allergy and Clinical Immunology 2014 133, 1608-1614.e6DOI: (10.1016/j.jaci.2013.11.012) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E1 Participants' disposition. Participants were randomized to one of the 3 groups, treated for approximately 12 months, and followed for the subsequent 12-month, immunotherapy-free period. Safety set year 1 was comprised of all participants who received at least 1 dose of investigational product. Safety set year 2 was comprised of all participants who completed year 1. Journal of Allergy and Clinical Immunology 2014 133, 1608-1614.e6DOI: (10.1016/j.jaci.2013.11.012) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E2 Immunologic markers (FASYear2). Serum specific IgE levels for D pteronyssinus (A) and D farinae (B) and serum specific IgG4 levels for D pteronyssinus (C) and D farinae (D) at baseline, month 12, and month 24. Journal of Allergy and Clinical Immunology 2014 133, 1608-1614.e6DOI: (10.1016/j.jaci.2013.11.012) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions